Agenus Presents Additional Clinical Responses and Novel Biomarker Data at SITC2020
November 09 2020 - 8:15AM
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with
an extensive pipeline of checkpoint antibodies, cell therapies,
adjuvants, and vaccines designed to activate immune response to
cancers and infections, today announced presentations on seven
novel programs at The Society for Immunotherapy of Cancer (SITC)
35th Anniversary Annual Meeting & Pre-Conference Programs (SITC
2020) on November 9-14, 2020.
“This year, our strong showing at SITC includes
new data and presentations on seven novel programs and
platforms,” said Dr. Jennifer Buell, President and
COO of Agenus. “Our focus is to deliver curative cancer treatments
with our best-in-class inventions. We believe that our science
along with our broad portfolio of immuno-oncology agents give us
the ability to match patients to therapies using optimal
combinations. At SITC, we will present additional clinical
responses with our Fc-enhanced anti-CTLA-4, AGEN1181, advances with
our VISION responder prediction platform, and data on four other
clinical-stage programs.”
Presentation
Highlights:
AGEN1181 (Fc-enhanced CTLA-4) +/-
balstilimab (Agenus’
anti-PD-1) shows
additional clinical responses
in tumors which are “biomarker unlikely” to respond;
first-ever clinical
data on
intratumoral
Treg depletion with a CTLA-4
antibody:
- CR in PD-L1(-) MSS endometrial cancer patient
(1181 monotherapy)
- CR measured by PET in PD-L1(-) MSS endometrial
cancer patient (1181 + bali)
- PR in PD-L1(-) refractory ovarian cancer
patient (rescued with 1181 + bali) – previous stable disease for 66
weeks with 1181 monotherapy
- Major tumor
reduction (27%) in MSS colorectal cancer patient –
CEA biomarker declined from 298 to 2 (1181 + bali)
- Benefit seen in patients with polymorphism in
FcyRIIIA alleles who don’t respond to
first-generation CTLA-4
antibodies
- First-ever clinical report of selective depletion of
intratumoral Tregs with a CTLA-4
antibody
- No
complement-mediated
toxicities
AGEN Fc-enhanced anti-TIGIT antibodies
- Significant superiority vs other TIGIT antibodies
- Potential to broaden benefit to patients with low and high
affinity FcyIIIA alleles; akin to AGEN1181
- Superior NK cell activation, T cell
responsiveness, and antigen-specific CD8 T cell memory compared to
other clinical-stage TIGIT antibodies
AGEN2373, an
anti-CD137 agonist
monotherapy,
shows clinical benefit without liver
toxicity
- SD in 4 patients with durable disease
stabilization in an ovarian cancer patient
- No liver toxicity in patients dosed up to 1mg/kg
- AGEN2373 clinical data indicate
increased trafficking of CD8 and CD4 T cells, and mature NK cells
in the tumor microenvironment; 2373 also promotes robust depletion
of intratumoral Tregs
AgenT-797, a
clinical-stage
allogeneic iNKT cell
therapy, demonstrates
direct tumor killing, tumor microenvironment
conditioning;
lower-cost scalable
manufacturing
- iNKT cells promote direct tumor killing and tumor
microenvironment conditioning demonstrated with biomarkers for both
Th1 and Th2 activation
- Efficient and low-cost manufacturing process yielding more than
100 treatments from a single source with process development to
yield 1000 treatments
- iNKTs can also be engineered with CAR technology
VISION – AGENUS’ proprietary
time-lapse biomarker
platform designed to
predict responses and
define effective combinations
- Deep in vitro profiling, functional genomics, and Al-based
approaches to predict clinical outcomes and identify optimal
targets and combinations
- VISION predicted responses to anti-PD-1 with 87% accuracy in
melanoma and 86% accuracy in cervical cancer
- Identified enhanced cytotoxicity of
anti-PD-1 and anti-TIGIT combination
Agenus ePosters and corresponding audio will be available
for viewing in the Poster
Hall beginning November 9th at
8am. In addition, the presenting authors
will be available for live discussions at the following times:
Abstract title: AGEN1181, an Fc engineered anti-CTLA-4
antibody, demonstrates clinical activity, alone or in combination
with balstilimab (anti-PD-1), and broadens the therapeutic
potential of CTLA-4 therapy
(NCT03860272)Abstract
number: 398Presenting author: Dr. Stephen O’DayLive discussion
times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pm
Abstract title: Single-agent Zalifrelimab (anti-CTLA-4)
Shows Clinical Benefit in Rare Tumors - Case Report from Phase 2
Study (NCT03104699)Abstract number: 256Presenting author:
Dr. Cesar PerezLive discussion times: 11/12 4:50-5:20pm; 11/14
1:00-1:30pm
Abstract title: AGEN2373 is a CD137 agonist antibody
designed to leverage optimal CD137 and FcγR co-targeting to promote
antitumor immunologic effectsAbstract number:
377Presenting author: Dr. Claire GalandLive discussion times: 11/11
5:15-5:45; 11/13 4:40-5:10pm
Abstract title: Pseudoprogression Patterns: Analysis
from 2 Independent Phase-2 Studies with Immunotherapy for Recurrent
Cervical CancerAbstract number: 267Presenting author: Dr.
David O’MalleyLive discussion times: 11/11 5:15-5:45pm; 11/13
4:40-5:10pm
Abstract title: AgenT-797, a novel allogenic and
“off-the shelf” iNKT cell therapy promotes effective tumor
killingAbstract number: 164Presenting author: Dr. Burcu
YigitLive discussion times: 11/12 4:50-5:20; 11/14 1:00-1:30pm
Abstract title: Anti-TIGIT antibodies require enhanced
FcγR co-engagement for optimal T and NK cell-dependent anti-tumor
immunityAbstract number: 253Presenting author: Rebecca
WardLive discussion times: 11/11 5:15-5:45pm; 11/13 4:40-5:10pm
Abstract title: Beyond PD-L1: novel PD-1 biomarkers
identified by driving T cell dysfunction in vitroAbstract
number: 70Presenting author: Dr. Simarjot PablaLive discussion
times: 11/12 4:50-5:20pm; 11/14 1:00-1:30pm
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer. The
Company's vision is to expand the patient populations benefiting
from cancer immunotherapy by pursuing combination approaches that
leverage a broad repertoire of antibody therapeutics, adoptive cell
therapies (through its AgenTus Therapeutics subsidiary), and
proprietary cancer vaccine platforms. The Company is equipped with
a suite of antibody discovery platforms and a state-of-the-art GMP
manufacturing facility with the capacity to support clinical
programs. Agenus is headquartered in Lexington, MA. For more
information, please visit www.agenusbio.com and our Twitter handle
@agenus_bio. Information that may be important to investors will be
routinely posted on our website and Twitter.
Forward-Looking StatementsThis press release
contains forward-looking statements that are made pursuant to the
safe harbor provisions of the federal securities laws, including
statements regarding the therapeutic and curative potential of
Agenus’ product candidates and the potential capabilities of
Agenus’ VISION platform. These forward-looking statements are
subject to risks and uncertainties that could cause actual results
to differ materially. These risks and uncertainties include, among
others, the factors described under the Risk Factors section of our
most recent Quarterly Report on Form 10-Q or Annual Report on Form
10-K filed with the Securities and Exchange Commission. Agenus
cautions investors not to place considerable reliance on the
forward-looking statements contained in this release. These
statements speak only as of the date of this press release, and
Agenus undertakes no obligation to update or revise the statements,
other than to the extent required by law. All forward-looking
statements are expressly qualified in their entirety by this
cautionary statement.
Contact:Agenus
Inc. Caroline
Bafundo212-994-8209Caroline.Bafundo@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024